Advertisement
Advertisement

ATRA

ATRA logo

Atara Biotherapeutics, Inc

8.34
USD
Sponsored
-1.59
-16.01%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

9.35

+1.01
+12.11%

Atara Biotherapeutics, Inc Profile

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.

Info & Links

CEO

AnhCo Thieu Nguyen

Headquarters

1280 RANCHO CONEJO BLVD
THOUSAND OAKS, CA 91320, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.atarabio.com

Auditor

Deloitte & Touche LLP

Share holders

5

Employees

14

Atara Biotherapeutics, Inc Statistics

Valuation Measures

Market Capitalization2

79.59M

Enterprise Value

71.11M

Enterprise Value/EBITDA(ttm)

1.86

Price to Earnings Ratio(ttm)

1.55

Price to Sales(ttm)

0.33

Price to Book(mrq)

--

Price to Cash(ytd)

0.99

Profitability

Gross Margin(ttm)

91.54%

Operating Margin(ttm)

27.07%

Profit Margin(ttm)

-71.46%

Return on Equity(ttm)

-79.12%

Return on Invested Capital(ttm)

-55.24%

Return on Assets(ttm)

87.55%

Income Statement

Revenue(ttm)

120.77M

Revenue Per Share(ttm)

14.77

Gross Profit(ttm)

99.56M

EBITDA(ttm)3

38.24M

Net Income Available to Common(ttm)

32.69M

Diluted EPS(ttm)

3.12

Share Statistics

Beta (5Y Monthly)

-0.34

52-Week Change

12.40%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

8.18M

Dividend Yield

0.00%

Float4

7.85M

% Held by Insiders

4.00%

% Held by Institutions

70.90%

Balance Sheet

Total Cash(mrq)

8.48M

Total Cash Per Share(mrq)

1.04

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

0.82%

Quick Ratio(mrq)

0.82%

Book Value Per Share(mrq)

-5.26

Cash Flow

Operating Cash Flow Per Share(ytd)

-4.01

Free Cash Flow(ytd)

-49.99M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement